HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP-744809

aldose reductase inhibitor (ARI) of the structural class, pyridazinones; structure in first source

Also Known As:

ARI-809

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridazines: 11
    - CP-744809: 1

Experts

1.	Coutcher, James B: 1 article (10/2006)
2.	Gerhardinger, Chiara: 1 article (10/2006)
3.	Lorenzi, Mara: 1 article (10/2006)
4.	Oates, Peter J: 1 article (10/2006)
5.	Sun, Wei: 1 article (10/2006)

Related Diseases

1.	Cataract (Cataracts) 10/01/2006 - "ARI-809 improved survival, inhibited cataract development, normalized retinal sorbitol and fructose, and protected the retina from abnormalities that also occur in human diabetes: neuronal apoptosis, glial reactivity, and complement deposition. "
2.	Hyperglycemia 10/01/2006 - "Because ARI-809 is a novel chemotype highly selective for aldose reductase, these results support the notion that aldose reductase is the key relay that converts hyperglycemia into glucose toxicity in neural and glial cell types in the retina."

Related Drugs and Biologics

1.	Sorbitol (Yal)
2.	Retinaldehyde (Retinal)
3.	Fructose
4.	Complement System Proteins (Complement)
5.	Glucose (Dextrose)
6.	Aldehyde Reductase (Aldose Reductase)